196 results on '"Lee, John K."'
Search Results
2. Development of Cancer Immunotherapies
3. A combinatorial genetic strategy for exploring complex genotype–phenotype associations in cancer
4. Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study
5. Supplementary Figure 14 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
6. Supplementary Figure 8 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
7. Data from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
8. Supplementary Figure 16 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
9. Supplementary Table 3 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
10. Supplementary Figure 5 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
11. Supplementary Figure 3 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
12. Supplementary Figure 6 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
13. Data from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
14. Supplementary Figure 13 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
15. Supplementary Table 1 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
16. Supplementary Figure 7 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
17. Supplementary Figure 5 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
18. Supplementary Figure 11 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
19. Supplementary Figure 9 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
20. Supplementary Figure 1 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
21. Supplementary Figure 15 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
22. Supplementary Figure 17 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
23. Concurrent targeting of HDAC and PI3K to overcome phenotypic heterogeneity of castration-resistant and neuroendocrine prostate cancers
24. Targeting the fibroblast growth factor pathway in molecular subtypes of castration‐resistant prostate cancer
25. Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models
26. LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase function
27. Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting
28. Sarcomatoid Urothelial Carcinoma Is Associated With Limited Response to Neoadjuvant Chemotherapy and Poor Oncologic Outcomes After Radical Cystectomy
29. Expanding the landscape of TCR gene therapy targeting MAGE
30. Identification of Cell Surface Targets for CAR T Cell Immunotherapy
31. Precision Medicine-Enabled Cancer Immunotherapy
32. Large libraries of single-chain trimer peptide-MHCs enable antigen-specific CD8+ T cell discovery and analysis
33. Combinatorial genetic strategy accelerates the discovery of cancer genotype-phenotype associations
34. Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy
35. Data from Comprehensive Assessment of Anaplastic Lymphoma Kinase in Localized and Metastatic Prostate Cancer Reveals Targetable Alterations
36. Data from Comprehensive Assessment of Anaplastic Lymphoma Kinase in Localized and Metastatic Prostate Cancer Reveals Targetable Alterations
37. Supplementary Figures 1-19, Tables 1-2 from Comprehensive Assessment of Anaplastic Lymphoma Kinase in Localized and Metastatic Prostate Cancer Reveals Targetable Alterations
38. Supplementary Figures 1-19, Tables 1-2 from Comprehensive Assessment of Anaplastic Lymphoma Kinase in Localized and Metastatic Prostate Cancer Reveals Targetable Alterations
39. Supplementary Methods, Supplementary Figures 1-6 from Targeting RET Kinase in Neuroendocrine Prostate Cancer
40. Supplementary Tables 1-8 from Targeting RET Kinase in Neuroendocrine Prostate Cancer
41. Supplementary Tables 1-8 from Targeting RET Kinase in Neuroendocrine Prostate Cancer
42. Supplementary Methods, Supplementary Figures 1-6 from Targeting RET Kinase in Neuroendocrine Prostate Cancer
43. Entropic analysis of antigen-specific CDR3 domains identifies essential binding motifs shared by CDR3s with different antigen specificities
44. Transcriptional-translational conflict is a barrier to cellular transformation and cancer progression
45. Supplementary Materials and Methods from RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer
46. Supplementary Figures S1-S13 from RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer
47. Supplementary Tables S1-S12 from RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer
48. Supplementary Materials and Methods from RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer
49. Figure S3 from Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer
50. Supplementary Data from PEG10 Promoter–Driven Expression of Reporter Genes Enables Molecular Imaging of Lethal Prostate Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.